Background Ropivacaine has an optimal toxicity profile for epidural anesthesia in adults, but there are currently no studies concerning its pharmacokinetics during continuous infusion. The primary objective of this study was to evaluate the pharmacokinetics and safety of ropivacaine in adults during a 48-h continuous epidural infusion. Materials and methods We enrolled 43 adults (ASA I-II) scheduled for major abdominal or urologic surgery with postoperative continuous epidural analgesia with ropivacaine 0.2% (5 mL/h) and sufentanil 0.75 μg/mL for 48 h.
Introduction
Ropivacaine (RPV) is a long-acting amide-type local anesthetic with a similar structure to bupivacaine [1] . Many literature studies have demonstrated the clinical efficacy of ropivacaine 0.2% epidural infusion, with only some individual case reports of major side effects [2] [3] [4] [5] . Although ropivacaine is a safer alternative to bupivacaine, excessive plasma concentrations of ropivacaine can cause severe central nervous system and cardiac toxicity. After epidural administration, both the systemic absorption and the systemic disposition of ropivacaine play an important role in determining the clinical profile and the risk of systemic toxicity [6] [7] .
Ropivacaine's calculated terminal half-life is significantly longer after epidural than after intravenous administration. Ropivacaine absorption after epidural administration cannot be derived directly from plasma concentration-time curves because of flip-flop kinetics [7, 8] . The flip-flop model implies that slow absorption of ropivacaine from the epidural space into the systemic circulation rate-limits drug elimination. Therefore, when the process of absorption is a limiting factor, the terminal half-life reflects the rate and the extent of absorption and not the elimination process [8, 9] . In a system consisting of a series of processes, the decrease in concentrations after administration is discontinued and the time to reach the steady-state depends on the slowest process in the chain. This has implications for designing epidural continuous infusion schedules of ropivacaine, considering the clinical significance of accumulation reaching either toxic or ineffective concentrations.
The primary goal of this study was to evaluate the pharmacokinetics of ropivacaine accumulation in adults receiving continuous epidural analgesia during the first 48 h after major surgery.
Materials and methods

After approval from the Ethics Committee of San Matteo
Hospital (EudraCT number 2010-019393-32) and written informed consent, 49 adult patients, ASA class I-II, scheduled for major abdominal or urological surgery and planned to receive a postoperative epidural infusion after surgery for pain control were enrolled. Exclusion criteria were emergency surgery; coagulopathy; renal, hepatic, neurological, or psychiatric diseases; a history of peripheral neuropathies; and chronic opioid therapy.
Before anesthesia induction, an epidural catheter was positioned with the patient in the sitting position, using the loss resistance technique. In patients scheduled for upper abdominal surgery, the epidural catheter was placed between T7 and T8 or T9 and T10. In patients scheduled for lower abdominal or urologic surgery, it was placed between T10 and T11. General anesthesia was induced with propofol 2 mg/kg, fentanyl 2 μg/kg, and cisatracurium 0.15 mg/kg, and was maintained with fentanyl and sevoflurane 2%. Forty-five minutes before the end of surgery, patients received an epidural loading dose (RPV 0.2% 5 ml+sufentanil 10 μg), followed by a second bolus (RPV 02% 5 ml) 15 min later. At the end of surgery, an epidural infusion of ropivacaine 0.2% plus sufentanil 0.8 μg/ml was started. Ropivacaine/sulfentanyl epidural infusion was constantly codelivered at a rate of 5 ml/h using an electronic infusion pump during the first 48 h after surgery.
Patients were evaluated every 6 h during the first day after surgery and every 12 h in the second postoperative day. We recorded vital signs (arterial pressure and heart rate), pain according to the Numeric Rate Scale (at rest: NRS, and after movement: mNRS), analgesic rescue dose (administered if NRS>4), Holmen scale (to assess if there was sensory block), sedation scale, and clinical side effects (nausea, vomiting, itching, hypotension, systemic neurological side effects) Reagents RPV was a gift of the Department of Anesthesia and Intensive Care. Phenacetin was purchased from Sigma (St. Louis, MO, USA). All other chemicals and reagents used were of the highest commercially available quality.
Instrumentation
The HPLC system consisted of Varian Prostar Mod. 430, a pump equipped with variable-wavelength UV detector (Varian Prostar Mod.330). Separation was achieved using a reverse-phase C-18 column (250×4.6 mm I.D., particle size 5 μm, Hypersil BDS-CPS Analitica, Italy). The mobile phase was acetonitrile, methanol, 50 mM potassium dihydrogen phosphate (pH=6) (180:160:660, v/v/v) delivered at a flow rate of 1.3 mL/min. Chromatographic separation was performed at laboratory room temperature and monitored at 210 nm.
The HPLC method has been validated over the range 0.1-4 μg/mL. The assay was linear over the entire concentration range (R 2 =0.99). Intra-and interday precision and accuracy were less than 6%.
The limit of detection (LOD) was 0.050 μg/mL, the limit of quantification (LOQ) was 0.1 μg/mL.
Preparation of standard solution and standard curves
A standard stock solution (1 mg/mL) of drug was prepared in methanol-water (50/50), stored at −20°C, and was stable for at least 6 months. Plasma standards and controls were prepared at concentrations of 0.1, 0.2, 0.4, 1.0, 2.0, 4.0 μg/mL and 0.12 (low), 0.8 (medium), and 1.6 (high)μg/mL, respectively, by diluting appropriate aliquots of the stock solution with drug-free serum. The calibration curve was obtained by linear regression of the peak-height ratios of ropivacaine to the internal standard and plotting these against the nominal concentration of the drug.
Blood sampling
Blood samples were obtained immediately before bolus drug administration and 3, 6, 12, 24, 48, 54, and 60 h after starting the infusion. Plasma was separated by centrifugation, transferred to clean prelabeled tubes, and frozen at −20°C until analysis.
Sample preparation
For sample preparation, 250 μL of distilled deionized water, 500 μL of dichloromethane, and 10 μL phenacetin (10 μg/mL, I.S.) were added to 250 μL of plasma. After vortex mixing for 3 min, the tubes were centrifuged at 1,200g for 10 min. The organic phase was transferred into a clean conical tube and evaporated to dryness under a gentle nitrogen stream. The residue was dissolved in 200 μL mobile phase, and 50 μL was injected into HPLC.
Pharmacokinetic analysis
The concentration-time relationship of ropivacaine levels (corresponding to six data points) during an epidural infusion preceded by two sequential boluses was analyzed using a population pharmacokinetic method based on a mixed-effectmodel approach. This method separates explicitly the variability of drug concentrations in the population into two parts: interindividual variability characterized by the distribution of pharmacokinetic parameters in the population and residual variability (e.g., measurement errors). A parametric approach [10, 11] was used (using the P-PHARM software, which is now incorporated into the Innaphase Kinetica suite) to estimate the mean and interindividual variance of each pharmacokinetic parameter in the population, to calculate the Bayesian maximum a posteriori estimates of individual pharmacokinetic parameters, and to test the relationships between these individual estimates and several covariates (gender, age, body weight, height, renal, and hepatic function indices). During covariate modeling, P-PHARM can automatically search for a linear relationship between covariates and the population parameter estimates.
Pharmacokinetic data were fitted with different compartmental models. The most appropriate model was chosen based on the Akaike information criterion [10] and the examination of residual plots. A one-compartment model with sequential bolus and infusion inputs was fitted to the total plasma ropivacaine concentration-time data.
The plasma concentration versus time curve of ropivacaine during continuous epidural infusion (R 0 : rate of epidural infusion) was described by the equation:
Àl DP :t λ DP indicates the "mixed" (absorption/distribution/elimination) rate constant of ropivacaine observed during 48 h epidural drug administration and calculated by the CL/Vd ratio. t 1/2,DP was defined as the 0.693/λ DP ratio and represents the infusion dosing half-life. Ropivacaine pharmacokinetic starting estimates for the population analysis were obtained from previous studies. A heteroscedastic error variance (1/Y) model was used to describe residual error, and a log-normal distribution was used to describe interpatient variability in apparent clearance (CL) and apparent volume of distribution (Vd).
When bioavailability (F) is not known, estimates of CL should be related to F, i.e., CL/F. Bioavailability was fixed to 1, assuming total (100%) absorption after epidural administration. Model evaluation was conducted as recommended in the P-PHARM manual and also by examination of a plot of measured/predicted concentration data versus time.
After the end of infusion, the terminal rate constant (λ terminal ) was determined for total ropivacaine by linear regression of the last three data points on the plasma concentration-time curve (from the 48th hour to the 60th hour):
Àl terminal Át 0 t 1/2,terminal was defined as the 0.693/λ terminal ratio and represents the terminal half-life after the infusion is stopped. t′ is the time since the end of the infusion. The area under the plasma concentration-time curve was calculated by numeric integration using the linear trapezoidal rule. C max was the highest concentration achieved; the time to C max (t max ) and the plasma concentrations at 3, 6, 12, 24, 48, 54, and 60 h after starting ropivacaine administration (C 3h , C 6h , C 12h , C 24h , C 48h , C 54h , C 60h , respectively) were derived directly from ropivacaine levels.
Statistical analysis
Patient characteristics are summarized as median values (range). Total plasma ropivacaine concentrations and derived pharmacokinetic data are summarized as geometric mean (geometric coefficient of variation, CV%) and/or mean (±SD) values. Multiple-linear regression analysis with stepwise inclusion between maximum a posteriori estimates of all pharmacokinetic parameters and all covariates was performed with the analysis of variance to determine the relevant relationships (with the P-PHARM software) [10] . A value of P < 0.05 was considered significant.
Results
Forty-nine adults were consecutively enrolled, and six were excluded after discontinuation of epidural continuous infusion because of clinical or hemodynamic problems not related to ropivacaine epidural infusion; data collection was incomplete in one other patient, whose data were nevertheless included in our PK analysis. Forty-three patients completed the analysis.
Thirty-five patients underwent major abdominal surgery and eight underwent urological surgery (29 males and 14 females). Patient age ranged from 41 to 83 years (median= 63 years) and body weight ranged from 50 to 100 kg (median= 75.5 kg). Analgesia was satisfactory in all cases and there were no cardiocirculatory side effects, such as major hypotension or arrhythmia, which could require discontinuation of the epidural infusion. There were no minor (facial dysthesia, tinnitus, changes in sensitivity and strength) or major (convulsions, hallucinations) neurological complications during continuous epidural infusion of ropivacaine.
A total of 330 plasma concentrations from 43 patients were used to compute pharmacokinetic parameters including a baseline sample, four samples collected during ropivacaine infusion, and three samples collected during the first 12 h after ropivacaine infusion discontinuation. Pharmacokinetic data (geometric mean and geometric coefficient of variation, CV%) are summarized in Table 1 .
During the epidural infusion (ropivacaine 10 mg/h) preceded by two sequential boluses of 10 mg each, plasma concentrations of ropivacaine leveled off, as expected. Exposure to ropivacaine during epidural infusion was highly variable.
The plasma concentration of ropivacaine at the end of epidural infusion (C 48h ) was 1.60±0.89 μg/mL. After 12 and 24 h, respectively, ∼50% and ∼75% of the 48-h level of ropivacaine had been reached. C max was 1.82±0.89 μg/mL and was observed at t max of 48 h.
Total plasma ropivacaine concentrations were mainly within (84%) or below (12%) the range reported to be safe in adults (1.0-3.00 μg/mL) [5, 6, 7, [12] [13] [14] . Only two patients (5%) reached ropivacaine plasma levels higher than 3.0 μg/mL, namely 3.8 and 4.0 μg/mL at 48 and 54 h, respectively. Total ropivacaine concentrations up to 4.0 μg/mL were tolerated during long-term epidural ropivacaine infusion. Figure 1 shows all the measured plasma ropivacaine concentrations and the drug concentration-time curve resulting from the average population parameters estimated with P-Pharm.
Estimated population characteristics of the kinetic parameters for ropivacaine clearance (CL) and the apparent volume of distribution (Vd) with their coefficients of variation are presented in Table 2 .
The dosing period absorption/distribution/elimination rate constant of ropivacaine calculated with the average population parameters (λ DP =CL/Vd) was 0.064 h -1 and the corresponding t 1=2;DP ¼ 0:693 » Vd ð Þ =CL ¼ 10:8hours. Following the end of epidural infusion of ropivacaine, the terminal half-life (t 1/2,terminal ) determined for total ropivacaine by linear regression of the last three data points on the plasma concentration-time curve was 7.4 h.
The pharmacokinetic population parameters were subsequently used to fit the concentration data up to 48 h using PK the Bayesian estimation method. This procedure enables the estimation of individual pharmacokinetic parameters for ropivacaine. The individual posterior Bayesian estimates of ropivacaine pharmacokinetic parameters were generated using a maximum a posteriori probability Bayesian fitting procedure [21] . The performance of individualized Bayesian estimation steps is shown in the plots of the observed versus estimated plasma concentrations in Fig. 2 , and by the frequency distribution histogram of the normalized residuals which revealed a distribution very close to the expected one (normal with zero mean and unitary variance).
Through covariate analysis, we found that age was the only independent predictor identified.
In fact, the stepwise inclusion performed on P-PHARM revealed an age effect on CL that explains 39.8% of the interindividual variability of the population pharmacokinetic parameters. Ropivacaine clearance correlated inversely with age. The linear correlation between age and ropivacaine clearance was best described by the equation (least square regression; r=0.63, P<0.001):
CL L=h ð Þ ¼ 14:9 À 0:15 Â age years ð Þ
Discussion
The pharmacokinetics of epidural ropivacaine was well described after single dose, but it is important to detect what can happen during continuous infusion. Therefore we investigated the kind of kinetics we have during epidural continuous infusion and if there are predictors that can determine a change in the pharmacokinetic profile. In fact, plasma concentration profiles and the potential risk of systemic toxicity after epidural administration of ropivacaine depend on the administered dose and the interaction between the rate processes involved in drug absorption and systemic disposition [2, [14] [15] [16] [17] . Unfortunately, absorption and disposition kinetics cannot be derived directly from the plasma concentration-time profile, since local anesthetics exhibit flip-flop kinetics after epidural administration. In a system consisting of a series of processes or compartments, not only the decrease in the concentrations after stopping administration but also the time to reach steady-state depends on the slowest process in the chain.
Half-life is the most clinically relevant pharmacokinetic parameter to predict drug accumulation time in a patient upon constant rate administration. Problems arise when we have to pick the half-life upon which to calculate drug accumulation. Also, when estimating the time for the epidural administration to achieve steady-state, we have to decide if we should work with the actual elimination halflife of ropivacaine obtained from the PK of the intravenous formulation (t 1/2,IV ), consider the terminal half-life calculated after the end of the infusion (t 1/2,terminal ), or take into account the "mixed" absorption/distribution/elimination half-life estimated during the epidural infusion (t 1/2,DP ).
When the process of absorption is not a limiting factor, half-life is a hybrid parameter controlled by plasma Fig. 1 Total plasma ropivacaine concentration versus time curve during and after an epidural continuous infusion of 10 mg/h preceeded by two sequential epidural boluses. The solid line shows the computer-generated line of the best fit up to 48 h, for a one-compartment model with zero-order input and firstorder elimination clearance and extent of distribution. When the process of absorption is a limiting factor, the terminal half-life reflects mainly the rate and extent of absorption and not the elimination process (flip-flop pharmacokinetics) [18] . Our data indicate that the true half-life of ropivacaine, as reported after IV administration (t 1/2,IV 1.8±0.7 h) [19] , is irrelevant to the time to reach steady-state. In order to predict drug accumulation upon epidural infusion dosing, it is more appropriate to use the apparent infusion dosing half-life t 1/2,DP since this parameter appears to better reflect the interplay interference between volume distribution and absorption rate during the accumulation phase. Our data indicate that this infusion dosing period half-life (t 1/2,DP =10.8 h) was higher (↑45%) than the terminal half-life (t 1/2,terminal =7.4 h); a more pronounced sensitivity of the t 1/2,DP to the absorption rate process probably explains the difference. This difference seems to confirm the recommendation by Sahin and Benet [20] to avoid the uncritical use of a drug's terminal half-life to predict the drug's accumulation rate.
A one-compartment model with zero-order input and first-order elimination was optimal for describing the data in the accumulation phase during epidural infusion of ropivacaine. The same model was used by Hansen et al. [14] to describe the trend of ropivacaine concentrations during the accumulation phase in pediatric patients (mean age: 3.3 years, range: 0.3-7.3 years) under continuous epidural infusion. In the majority of children ropivacaine concentrations had reached the steady-state within 36 h and the half-life (t 1/2,DP ) of total ropivacaine was 4. On the other hand, the final parameters of ropivacaine obtained by a population pharmacokinetic analysis [21] (NONMEN) after loco-regional administration as an anesthetic in hip or knee replacement surgery were quite similar: the apparent clearance was 3.5 L/h and the volume of distribution was 65.3 L. When evaluating the individual pharmacokinetic parameters, though, we must keep in mind that modeling is always dangerous if no IV data are available, because we may get a good fit of data to our equations but the parameters are hybridized and therefore incorrect. It has been underlined that when one models with sums of exponentials, one can simply assume consistency (best to assume this for the equation and not the model). Thus, good fits do not validate our model but only indicate consistency. In most cases, like this one, it is not strictly necessary to assume validation [18] . Modeling with sums of exponentials is feasible, as long as the results are reported in terms of macroscopic parameters (coefficients and exponents) and model-independent parameters, such as mean systemic or oral clearance, which is always dose over AUC (Table 2) . For a drug such as ropivacaine, the time to reach the steady-state may be influenced by the absorption rate (if administered by extravascular route), by the volume of distribution, and by clearance; however, mean steady-state concentration depends only on clearance. Also, it is well recognized that clearance (divided by bioavailability) defines the appropriate rate of administration of a particular drug through the relationship: R 0 =CL×C ss,ave × F. For ropivacaine (10 mg/h), a drug following linear kinetics, the predicted concentration at steady-state, C ss,ave , based on individual a posteriori Bayesian estimates of ropivacaine pharmacokinetic clearance resulted in a mean value of 2.0 (±0.62)μg/mL. At the end of infusion (48 h after the start of treatment) the ropivacaine plasma levels achieved corresponded on average to ∼90% of the levels that would be achieved at the steady-state.
Our data showed that prediction of ropivacaine accumulation can be improved by considering patient age. After epidural infusion, a trend towards a lower total plasma clearance with increasing age was observed (Fig. 3) . Simon et al. [22] . studied the influence of age on pharmacokinetics of ropivacaine after single epidural administration and reported similar results: clearance is significantly decreased in the oldest patients relative to the youngest ones. In our study we confirmed that also during continuous infusion there is an inverse correlation between age and clearance. In fact RPV clearance in a 40-year-old individual is about twice as high as in a 70-year-old subject. As ropivacaine is extensively metabolized in the liver [7] , the age dependence in clearance may presumably reflect decreased enzyme activity.
Studies during prolonged epidural infusion of ropivacaine showed that postoperative increases in plasma alpha 1 -acid glycoprotein concentrations are associated with increases in the plasma protein binding and in the total plasma concentrations of ropivacaine. Ropivacaine total clearance depends on liver enzyme activity and on the free drug fraction in plasma (CL∼CL i × f u ; CL i =drug intrinsic clearance, f u = unbound drug fraction), while the clearance of the unbound drug depends solely on enzyme activity [23, 24] . Therefore, changes in the fraction bound to proteins (alpha 1 -acid glycoprotein) may affect the drug's total clearance but might also alter the relationship between total drug concentration and possible toxic effects [24] [25] [26] . We did not measure alpha 1 acid glycoprotein concentrations and to some extent this is a limitation of our study. However, the postoperative course of the patients included in our trial did not exhibit any pathophysiological changes other than those expected in patients undergoing this type of surgical procedure.
In conclusion, we demonstrate that during continuous epidural infusion of ropivacaine there is flip-flop kinetics and that we have to avoid the uncritical use of a drug's terminal half-life to predict the drug's accumulation rate. Furthermore, we found an equation that could correlate the ropivacaine clearance to age during epidural continuous infusion. It will be necessary to perform other trials in order to improve ropivacaine dosage individualization on the basis of pharmacokinetic data of patients.
